Skip to main content
Hajj And Omrah
About SFDA
About SFDA
نظرة عامة
Authority Establishment
Authority Membership
Authority Activities
Authority Management
Board of directors
SFDA in vision 2030
Vision Realization Office
National Transformation Program
Health Sector Transformation Program
National Industrial Development and Logistics Program
Authority Strategy
Strategy
Authority Values
Annual Reports
Career and Life
Life in SFDA
Career General Goals
Information Lists
All
The Authority
Food
Drugs
Medical Devices
الأعلاف
Pesticides
Laboratories
Cosmetics
Tobacco
Halal
Nutrition
Areas
All
The Authority
Food
Drugs
Medical Devices
الأعلاف
Pesticides
Laboratories
Cosmetics
Tobacco
Halal
Nutrition
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
نظرة عامة
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Evaluation Program
Decisions
نظرة عامة
Laws and Regulations
Guidelines
Drugs Circulars
forms
Circulars
FAQ
Sector Committee
نظرة عامة
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Studies and Research
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
نظرة عامة
Laws and Regulations
Guidelines
Forms
Circulars
FAQ
نظرة عامة
Scientific reports and statements
Laws and Regulations
Guidelines
Consumer Corner
Awareness Campaign
Topics of Interest
Interactive calculators
Media Centre
News
Rumours
Warnings
Events
Workshops
ميديا
Podcasts
Forms
Scientific Magazines And Articles
Eservices
All
The Authority
Food
Drugs
Medical Devices
الأعلاف
Pesticides
Laboratories
Cosmetics
Tobacco
Halal
Nutrition
Font Resize
+A
A
-A
Contrast
عربي
Hajj And Omrah
About SFDA
About SFDA
نظرة عامة
Authority Establishment
Authority Membership
Authority Activities
Authority Management
Board of directors
SFDA in vision 2030
Vision Realization Office
National Transformation Program
Health Sector Transformation Program
National Industrial Development and Logistics Program
Authority Strategy
Strategy
Authority Values
Annual Reports
Career and Life
Life in SFDA
Career General Goals
Information Lists
All
The Authority
Food
Drugs
Medical Devices
الأعلاف
Pesticides
Laboratories
Cosmetics
Tobacco
Halal
Nutrition
Areas
All
The Authority
Food
Drugs
Medical Devices
الأعلاف
Pesticides
Laboratories
Cosmetics
Tobacco
Halal
Nutrition
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
نظرة عامة
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Evaluation Program
Decisions
نظرة عامة
Laws and Regulations
Guidelines
Drugs Circulars
forms
Circulars
FAQ
Sector Committee
نظرة عامة
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Studies and Research
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
نظرة عامة
Laws and Regulations
Guidelines
Forms
Circulars
FAQ
نظرة عامة
Scientific reports and statements
Laws and Regulations
Guidelines
Consumer Corner
Awareness Campaign
Topics of Interest
Interactive calculators
Media Centre
News
Rumours
Warnings
Events
Workshops
ميديا
Podcasts
Forms
Scientific Magazines And Articles
Eservices
All
The Authority
Food
Drugs
Medical Devices
الأعلاف
Pesticides
Laboratories
Cosmetics
Tobacco
Halal
Nutrition
Home
Search Results
Containing any of the words
Only of the type
All
Annual Report
Awareness Article
Awareness Campaign
calculators
Circulars
Clinical Trial
Conference
Cosmetics standards Project
Cosmetics Warning
covid pages
Drug Clinical Trial
Drug evaluation reports
Drug Membership
Drug Safety Labeling
Eservices
Event
Events
Excellent establishments list
Forms
Hajj card
HAPC Committee Decisions
head of board
hpac-members
Information List
International Standard
Laboratories
Lists
List Drugs Withdrawal
List of hospital that reported sides effects
List Registered Drugs
List Registered Pharmacies
List Shortage Drug
Marketed Products
Medical devices studies
Medical Report
Message
New SFDA Drug Approvals
Open Data
Periodic Safety
Podcasts
portables service
Reference repositories drugs
Regulations exceptions
Risk Minimization Activity
Risk Minimization Activity - New
Rumours
Safety Alert
Scientific reports and statement
sector committee
Sector Committee decisions
service providing facilities
Speakers
Standard
Standards Projects For Medical Devices
Surveys
test
Vaccine Safety
Warnings
Drug Log
List Under registration Drugs / Under committee review
News
Scientific Magazines and articles
Warehouse
A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation
Drug Clinical Trial
A multinational, open-label, randomised, controlled trial to investigate efficacy and safety of NNC0365-3769 (Mim8) in adults and adolescents with haemophilia A with or without inhibitors.
Drug Clinical Trial
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight related complications or risk factors for CVD
Drug Clinical Trial
A Randomized, Open-label Trial of Paritaprevir Plus Ritonavir Plus Ombitasvir in the Treatment of HCV Genotype 4 Infected Patients with Stage 4-5 Chronic Kidney Disease
Drug Clinical Trial
A multicenter, multinational, prospective, observational study to describe the clinical outcomes in patients with type 2 diabetes mellitus, treated with insulin glargine 300 U/mL (insulin glargine U300) before, during and after the period of Ramadan / ORION study
Drug Clinical Trial
A Phase II, Multi-centre Open Label Study to Assess the Efficacy and Safety of Oral Apabetalone with Background Dapagliflozin in Subjects with Long -COVID-19 (Post-COVID-19 Conditions) and Type 2 Diabetes Mellitus (T2DM)
Drug Clinical Trial
Randomized, Phase 3, double-blind, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active IgG4- related disease
Drug Clinical Trial
Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Slow Repeated IV Infusions of 2 Doses of Doxorubicin Transdrug™ (DT) (20mg/m2 and 30mg/m2) to Those of Best Standard of Care (BSC) in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure or Intolerance to Sorafenib. ReLive Study.
Drug Clinical Trial
Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Slow Repeated IV Infusions of 2 Doses of Doxorubicin Transdrug™ (DT) (20mg/m2 and 30mg/m2) to Those of Best Standard of Care (BSC) in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure or Intolerance to Sorafenib. ReLive Study.
Drug Clinical Trial
"A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlledClinical Study to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729)in Pediatric Participants (ages 10 to 17 years, inclusive) with Type 2 Diabetes Mellitus"
Drug Clinical Trial
Pagination
First page
« First
Previous page
‹ Previous
…
الصفحة
114
الصفحة
115
الصفحة
116
الصفحة
117
Current page
118
الصفحة
119
الصفحة
120
الصفحة
121
الصفحة
122
…
Next page
Next ›
Last page
Last »